ATH 25.0% 0.5¢ alterity therapeutics limited

https://www.statnews.com/pharmalot/2016/09/19/sarepta-fda-duchenn...

  1. 1,560 Posts.
    lightbulb Created with Sketch. 2
    https://www.statnews.com/pharmalot/2016/09/19/sarepta-fda-duchenne-behind-the-decision/

    Sorry to drag this subject out. Note that one particular name of interest on this forum is not included.
    A little too long to copy. Excerpt:
    “By allowing the marketing of an ineffective drug, essentially a scientifically elegant placebo, thousands of patients and their families would be given false hope in exchange for hardship and risk,” [Dr. Ellis Unger, acting director of the FDA’s Office of Drug Evaluation] wrote in a July 18 dispute report. “I argue that this would be unethical and counterproductive. There could also be significant and unjustified financial costs – if not to patients, to society.”

    He added that approval “would send the signal that political pressure and even intimidation – not science – guide FDA decisions…"
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(25.0%)
Mkt cap ! $26.19M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $27.94K 6.050M

Buyers (Bids)

No. Vol. Price($)
47 58163299 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 57489001 48
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.001 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 20524121
Last updated 15.46pm 28/03/2024 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.